Current achievements and future perspectives of metronomic chemotherapy

Adriana Romiti, Rosa Falcone, Michela Roberto, Paolo Marchetti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Summary: In recent years, many anticancer drugs have been tested at metronomic dosages for a variety of tumours. Mechanisms of action attributed to metronomic chemotherapy (MCT) include antiangiogenesis, immunomodulation, direct inhibition of tumour growth, effect on tumour initiating cells and the modulation of clonal evolution. An active clinical research, aimed at testing MCT in several cancers, has been conducted over the past 15 years. However, because the majority of available results come from earlier phase II studies, mainly performed in the area of breast cancer (BC), it is clear that there are areas still to be investigated. We considered current studies dealing with MCT according to the clinical setting of patients. Despite a certain degree of overlap, we were able to identify four main clinical indications for MCT: refractory disease and frailty of patients, advanced stage disease (requiring first and second-line therapy), early stage disease and maintenance therapy after induction chemotherapy. In addition, a section of this review has been addressed to the combination of MCT with immunotherapy following the growing interest in the reinstatement of immune-surveillance. Crucial questions, such as the definition of optimal schedules of continuously delivered, low-dose chemotherapy and the recognition and validation of predictive biomarkers, need to be further addressed. Moreover, comparisons with the best supportive care are especially lacking and thus urgently awaited to establish the key role of MCT in the care of pretreated and frail patients. Maintenance therapy promises to be one of the most worthwhile developments for MCT. Currently, several combination strategies with standard chemotherapy, target agents or immunotherapy are under investigation but further efforts are needed to fill the gaps of knowledge in this field.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalInvestigational New Drugs
DOIs
Publication statusAccepted/In press - Dec 1 2016
Externally publishedYes

Fingerprint

Drug Therapy
Immunotherapy
Clonal Evolution
Neoplasms
Induction Chemotherapy
Immunomodulation
Neoplastic Stem Cells
Combination Drug Therapy
Appointments and Schedules
Therapeutics
Biomarkers
Breast Neoplasms
Growth
Research
Pharmaceutical Preparations

Keywords

  • Elderly
  • Immunotherapy
  • Low-dose chemotherapy
  • Metronomic chemotherapy
  • Predictive biomarkers

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Current achievements and future perspectives of metronomic chemotherapy. / Romiti, Adriana; Falcone, Rosa; Roberto, Michela; Marchetti, Paolo.

In: Investigational New Drugs, 01.12.2016, p. 1-16.

Research output: Contribution to journalArticle

Romiti, Adriana ; Falcone, Rosa ; Roberto, Michela ; Marchetti, Paolo. / Current achievements and future perspectives of metronomic chemotherapy. In: Investigational New Drugs. 2016 ; pp. 1-16.
@article{dc304074dcc64c8fb1d8c66ade59bd0e,
title = "Current achievements and future perspectives of metronomic chemotherapy",
abstract = "Summary: In recent years, many anticancer drugs have been tested at metronomic dosages for a variety of tumours. Mechanisms of action attributed to metronomic chemotherapy (MCT) include antiangiogenesis, immunomodulation, direct inhibition of tumour growth, effect on tumour initiating cells and the modulation of clonal evolution. An active clinical research, aimed at testing MCT in several cancers, has been conducted over the past 15 years. However, because the majority of available results come from earlier phase II studies, mainly performed in the area of breast cancer (BC), it is clear that there are areas still to be investigated. We considered current studies dealing with MCT according to the clinical setting of patients. Despite a certain degree of overlap, we were able to identify four main clinical indications for MCT: refractory disease and frailty of patients, advanced stage disease (requiring first and second-line therapy), early stage disease and maintenance therapy after induction chemotherapy. In addition, a section of this review has been addressed to the combination of MCT with immunotherapy following the growing interest in the reinstatement of immune-surveillance. Crucial questions, such as the definition of optimal schedules of continuously delivered, low-dose chemotherapy and the recognition and validation of predictive biomarkers, need to be further addressed. Moreover, comparisons with the best supportive care are especially lacking and thus urgently awaited to establish the key role of MCT in the care of pretreated and frail patients. Maintenance therapy promises to be one of the most worthwhile developments for MCT. Currently, several combination strategies with standard chemotherapy, target agents or immunotherapy are under investigation but further efforts are needed to fill the gaps of knowledge in this field.",
keywords = "Elderly, Immunotherapy, Low-dose chemotherapy, Metronomic chemotherapy, Predictive biomarkers",
author = "Adriana Romiti and Rosa Falcone and Michela Roberto and Paolo Marchetti",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s10637-016-0408-x",
language = "English",
pages = "1--16",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Current achievements and future perspectives of metronomic chemotherapy

AU - Romiti, Adriana

AU - Falcone, Rosa

AU - Roberto, Michela

AU - Marchetti, Paolo

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Summary: In recent years, many anticancer drugs have been tested at metronomic dosages for a variety of tumours. Mechanisms of action attributed to metronomic chemotherapy (MCT) include antiangiogenesis, immunomodulation, direct inhibition of tumour growth, effect on tumour initiating cells and the modulation of clonal evolution. An active clinical research, aimed at testing MCT in several cancers, has been conducted over the past 15 years. However, because the majority of available results come from earlier phase II studies, mainly performed in the area of breast cancer (BC), it is clear that there are areas still to be investigated. We considered current studies dealing with MCT according to the clinical setting of patients. Despite a certain degree of overlap, we were able to identify four main clinical indications for MCT: refractory disease and frailty of patients, advanced stage disease (requiring first and second-line therapy), early stage disease and maintenance therapy after induction chemotherapy. In addition, a section of this review has been addressed to the combination of MCT with immunotherapy following the growing interest in the reinstatement of immune-surveillance. Crucial questions, such as the definition of optimal schedules of continuously delivered, low-dose chemotherapy and the recognition and validation of predictive biomarkers, need to be further addressed. Moreover, comparisons with the best supportive care are especially lacking and thus urgently awaited to establish the key role of MCT in the care of pretreated and frail patients. Maintenance therapy promises to be one of the most worthwhile developments for MCT. Currently, several combination strategies with standard chemotherapy, target agents or immunotherapy are under investigation but further efforts are needed to fill the gaps of knowledge in this field.

AB - Summary: In recent years, many anticancer drugs have been tested at metronomic dosages for a variety of tumours. Mechanisms of action attributed to metronomic chemotherapy (MCT) include antiangiogenesis, immunomodulation, direct inhibition of tumour growth, effect on tumour initiating cells and the modulation of clonal evolution. An active clinical research, aimed at testing MCT in several cancers, has been conducted over the past 15 years. However, because the majority of available results come from earlier phase II studies, mainly performed in the area of breast cancer (BC), it is clear that there are areas still to be investigated. We considered current studies dealing with MCT according to the clinical setting of patients. Despite a certain degree of overlap, we were able to identify four main clinical indications for MCT: refractory disease and frailty of patients, advanced stage disease (requiring first and second-line therapy), early stage disease and maintenance therapy after induction chemotherapy. In addition, a section of this review has been addressed to the combination of MCT with immunotherapy following the growing interest in the reinstatement of immune-surveillance. Crucial questions, such as the definition of optimal schedules of continuously delivered, low-dose chemotherapy and the recognition and validation of predictive biomarkers, need to be further addressed. Moreover, comparisons with the best supportive care are especially lacking and thus urgently awaited to establish the key role of MCT in the care of pretreated and frail patients. Maintenance therapy promises to be one of the most worthwhile developments for MCT. Currently, several combination strategies with standard chemotherapy, target agents or immunotherapy are under investigation but further efforts are needed to fill the gaps of knowledge in this field.

KW - Elderly

KW - Immunotherapy

KW - Low-dose chemotherapy

KW - Metronomic chemotherapy

KW - Predictive biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85001132627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001132627&partnerID=8YFLogxK

U2 - 10.1007/s10637-016-0408-x

DO - 10.1007/s10637-016-0408-x

M3 - Article

AN - SCOPUS:85001132627

SP - 1

EP - 16

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

ER -